1. Home
  2. MIRM
  3. MIRM News

Latest Mirum Pharmaceuticals Inc. (MIRM) News on July 27, 2024

MIRM

MT Newswires

a day ago

Mirum Pharmaceuticals Gets FDA Label Expansion Approval for Liver Disease Treatment; Shares Jump

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
MIRM

Business Wire

2 days ago

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone
MIRM

Simply Wall St.

14 days ago

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves
MIRM

Investor's Business Daily

14 days ago

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

16 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
MIRM

Zacks

17 days ago

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
MIRM

Zacks

18 days ago

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

MIRM

MT Newswires

18 days ago

Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
MIRM

Business Wire

19 days ago

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50
MIRM

Investor's Business Daily

a month ago

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50

MIRM

MT Newswires

a month ago

Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
MIRM

Business Wire

a month ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling
MIRM

Investor's Business Daily

a month ago

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling

MIRM

MT Newswires

a month ago

Stifel Adjusts Mirum Pharmaceuticals Price Target to $66 From $48, Maintains Buy Rating

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
MIRM

Zacks

a month ago

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

MIRM

MT Newswires

a month ago

Evercore ISI Adjusts Price Target on Mirum Pharmaceuticals to $62 From $53, Maintains Outperform Rating

MIRM

MT Newswires

a month ago

Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $71 From $60, Maintains Strong Buy Rating

MIRM

MT Newswires

a month ago

Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $64 From $38, Maintains Buy Rating

MIRM

MT Newswires

a month ago

JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating

MIRM

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $57 From $53, Maintains Overweight Rating

MIRM

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Mirum Pharmaceuticals to $39 From $31, Maintains Overweight Rating

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
MIRM

Zacks

a month ago

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

MIRM

MT Newswires

a month ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MIRM

MT Newswires

a month ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

MIRM

MT Newswires

a month ago

Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment

MIRM

MT Newswires

a month ago

Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating

MIRM

MT Newswires

a month ago

Baird Adjusts Mirum Pharmaceuticals Price Target to $39 From $34, Maintains Outperform Rating

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
MIRM

Business Wire

a month ago

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
MIRM

Business Wire

a month ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
MIRM

GuruFocus.com

a month ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

MIRM

Energy Global

a month ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
MIRM

USA TODAY

a month ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
MIRM

Business Wire

a month ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
MIRM

Business Wire

a month ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
MIRM

GlobeNewswire

a month ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
MIRM

Reuters

a month ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
MIRM

GlobeNewswire

a month ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

2 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
MIRM

Zacks

2 months ago

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
MIRM

Business Wire

2 months ago

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
MIRM

Business Wire

2 months ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC
MIRM

Pharmaceutical Technology

2 months ago

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC

MIRM

MT Newswires

2 months ago

Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
MIRM

Business Wire

2 months ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now
MIRM

Simply Wall St.

2 months ago

Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
MIRM

Business Wire

2 months ago

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
MIRM

Zacks

2 months ago

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns

When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable?
MIRM

Simply Wall St.

2 months ago

When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable?

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
MIRM

Business Wire

2 months ago

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
MIRM

Insider Monkey

2 months ago

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIRM

GuruFocus.com

3 months ago

Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss

MIRM

MT Newswires

3 months ago

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
MIRM

Zacks

3 months ago

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

MIRM

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Mirum Pharmaceuticals Inc Earnings Call

MIRM

GuruFocus.com

3 months ago

Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
MIRM

Business Wire

3 months ago

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
MIRM

Newsfile

3 months ago

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
MIRM

Zacks

3 months ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
MIRM

Zacks

3 months ago

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
MIRM

Zacks

4 months ago

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
MIRM

GuruFocus.com

4 months ago

Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
MIRM

GlobeNewswire

4 months ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
MIRM

Zacks

4 months ago

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
MIRM

Zacks

5 months ago

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript
MIRM

Insider Monkey

5 months ago

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
MIRM

Business Wire

5 months ago

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
MIRM

Zacks

5 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

MIRM

GuruFocus.com

5 months ago

Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ...

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?
MIRM

Zacks

5 months ago

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

According to a New Survey, This Coffee Brand Is the 3rd Most Popular Restaurant Chain in America -- and It Isn't Starbucks
MIRM

Motley Fool

6 months ago

According to a New Survey, This Coffee Brand Is the 3rd Most Popular Restaurant Chain in America -- and It Isn't Starbucks

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.
MIRM

Motley Fool

6 months ago

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

Alliance Resource (ARLP) to Post Q4 Earnings: What's in Store?
MIRM

Zacks

6 months ago

Alliance Resource (ARLP) to Post Q4 Earnings: What's in Store?

Stride Inc (LRN) Reports Record Revenue and Profitability, Raises Full Year Guidance
MIRM

GuruFocus.com

6 months ago

Stride Inc (LRN) Reports Record Revenue and Profitability, Raises Full Year Guidance

Pentair (PNR) to Report Q4 Earnings: What's in the Cards?
MIRM

Zacks

6 months ago

Pentair (PNR) to Report Q4 Earnings: What's in the Cards?

Steel Dynamics Announces Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast
MIRM

PR Newswire

6 months ago

Steel Dynamics Announces Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast

DOW Gets ISCC PLUS Certification for Freeport Facility
MIRM

Zacks

6 months ago

DOW Gets ISCC PLUS Certification for Freeport Facility

Triumph Financial (TFIN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
MIRM

Zacks

6 months ago

Triumph Financial (TFIN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
MIRM

Zacks

6 months ago

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

Dana Earns 'Top Employer 2024' Awards in 16 Countries, Regional Distinction for Europe, North America
MIRM

PR Newswire

6 months ago

Dana Earns 'Top Employer 2024' Awards in 16 Countries, Regional Distinction for Europe, North America

LyondellBasell (LYB) Recycling Project Chosen for EU Fund Grant
MIRM

Zacks

6 months ago

LyondellBasell (LYB) Recycling Project Chosen for EU Fund Grant

Following a 20% decline over last year, recent gains may please ZipRecruiter, Inc. (NYSE:ZIP) institutional owners
MIRM

Simply Wall St.

6 months ago

Following a 20% decline over last year, recent gains may please ZipRecruiter, Inc. (NYSE:ZIP) institutional owners

Why Fast-paced Mover AZZ (AZZ) Is a Great Choice for Value Investors
MIRM

Zacks

6 months ago

Why Fast-paced Mover AZZ (AZZ) Is a Great Choice for Value Investors

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Dana Again Named a Greatest Workplace for Diversity by Newsweek Magazine
MIRM

PR Newswire

6 months ago

Dana Again Named a Greatest Workplace for Diversity by Newsweek Magazine

Verona Pharma plc's (NASDAQ:VRNA) latest 11% decline adds to one-year losses, institutional investors may consider drastic measures
MIRM

Simply Wall St.

6 months ago

Verona Pharma plc's (NASDAQ:VRNA) latest 11% decline adds to one-year losses, institutional investors may consider drastic measures

Should You Invest in Mirum Pharmaceuticals (MIRM)?
MIRM

Insider Monkey

6 months ago

Should You Invest in Mirum Pharmaceuticals (MIRM)?

40 Cities with the Lowest Life Expectancy in the US
MIRM

Insider Monkey

6 months ago

40 Cities with the Lowest Life Expectancy in the US

Share on Social Networks: